Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar 15;8(3):3552-8.
eCollection 2015.

Five-year follow-up after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft nephropathy

Sheng-Qiang Xia  1 , Yu Fan  2 , Ming-Yue Tan  2 , Jun-Hua Zheng  1
Affiliations

Five-year follow-up after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft nephropathy

Sheng-Qiang Xia et al. Int J Clin Exp Med. .

Abstract

Chronic allograft nephropathy (CAN) is a major cause of graft loss in long-term kidney transplant recipients. To identify the safety and efficacy of conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in patients with CAN, we investigated 92 biopsy demonstrated CAN patients during a 5-year follow-up.45 patients were converted to sirolimus treatment (SRL group) and remaining 47 patients continued CNI immunosuppression (CNI group). Renal function, proteinuria, hepatic function, lipid level and blood routine examination were observed for 60 months in each group. During the period of conversion, serum creatinine was superior in SRL group to CNI group. It dropped significantly from (174.0 ± 62.8) umol/L to (150.7 ± 83.4) umol/L in SRL group whereas increased to (200.9 ± 73.5) umol/L in CNI group (P < 0.05). However, SRL group showed increased proteinuria, triglycerides and decreased Plt (P < 0.05). We also found those patients in SRL group with a good baseline of renal function (serum creatinine < 200 umol/L or proteinuria < 800 mg/day at conversion) would ameliorate the impaired renal function from CAN at 60 months. In conclusion, it is safe and effective to convert from CNI to SRL for patients with CAN in our long-term observation. Early conversion is associated with an improvement of renal function.

Keywords: Sirolimus; chronic allograft nephropathy; conversion treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Renal graft survival proportions in two groups during follow-up time. The percent survival of graft are about 71% and 51% in SRL and CNI group respectively. *P < 0.05.
Figure 2
Figure 2
The variety of SRL dose during the follow-up. The SRL dose decreased over time from 5.3 mg/day to 3.21 ± 1.65 mg/day for reaching the SRL trough concentration
Figure 3
Figure 3
Mean serum creatinine (SCcr) levels between SRL and CNI group during the conversion period. Following conversion to SRL, serum creatinine of patients with CAN declined gradually. *P < 0.05.
Figure 4
Figure 4
Linear correlation analysis between SRL trough concentration and average triglyceride level of the patients in SRL intra-group comparaision during the conversion period.
Figure 5
Figure 5
The changes in serum creatinine (A) and proteinuria (B) levels with a different baseline before and after conversion in SRL group. *P < 0.05. ***P < 0.01.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342:605–12. - PubMed
    1. Cecka JM. The UNOS Scientific Renal Transplant Registry--ten years of kidney transplants. Clin Transpl. 1997:1–14. - PubMed
    1. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med. 2002;346:580–90. - PubMed
    1. Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349:2326–33. - PubMed
    1. Kahan BD. Sirolimus: a comprehensive review. Expert Opin Pharmacother. 2001;2:1903–17. - PubMed

LinkOut - more resources